Vyne Therapeutics Inc Down 6.57% To $3.28 After Earnings Beat

Monday, November 13, 2023 - Vyne Therapeutics Inc (VYNE) reported upside earnings and revenues today.

Wall Street earnings per share (EPS) projections for Vyne Therapeutics Inc were at a loss of $1.97 per share. The company beat those estimates with an EPS loss of $1.75 per share. The loss of $1.75 per share (which represents a -11% EPS surprise) led to the company's profits rising 31% compared to last year when the firm reported an EPS loss of $2.52 per share. The increase in Vyne Therapeutics Inc's annual growth rate represents how the business is performing well amid recent economic conditions.

Revenues were upbeat at $114 thousand. That revenue figure represents a 31.74% decrease from the year ago quarter.

The stock is down 6.57% to $3.28 after the report.

Vyne Therapeutics Inc's revenues declined at a faster pace than earnings.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 50. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds.